Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations

Area of Science:

• Genetics
• Neuroscience
• Pharmacology

Background:

• Down syndrome (DS), or trisomy 21, is the leading genetic cause of intellectual disability (ID).
• Individuals with DS develop Alzheimer's disease (AD) neuropathology and often AD-like dementia.
• No current pharmacological treatments exist for ID or AD in DS.

Purpose of the Study:

• To review preclinical drug evaluations in the Ts65Dn mouse model of DS.
• To summarize the current status of human clinical trials for ID and AD in DS.
• To discuss the limitations of the Ts65Dn model and suggest future therapeutic targets.

Main Methods:

• Review of preclinical studies using the Ts65Dn mouse model.
• Analysis of drug selection, efficacy assessment, and outcome variability in studies.
• Summary of human clinical trial data for DS-related ID and AD.

Main Results:

• The Ts65Dn mouse model has shown promising results with various drugs rescuing DS-relevant learning, memory, and cellular deficits.
• These preclinical findings suggest potential for ameliorating or preventing cognitive deficits in individuals with DS.
• Human clinical trials are ongoing, but results are still being evaluated.

Conclusions:

• Pharmacological interventions show potential for treating cognitive deficits in Down syndrome.
• The Ts65Dn model provides valuable insights but has genetic limitations.
• Further research and identification of new therapeutic targets are crucial for developing effective treatments for DS.